Commment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A.

•We raised some methodological concerns and made some comments on the systematic review by Chiva and colleague.•To state that Cytoreduction & HIPEC is not beneficial in front line and platinum sensitive recurrence is highly disputable.•Anyway, the combined treatment should be offered in the context of clinical trial; randomized data are urgently needed.